Tianjin Chase Sun Pharmaceutical Co Ltd banner

Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026

Watchlist Manager
Tianjin Chase Sun Pharmaceutical Co Ltd Logo
Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026
Watchlist
Price: 3.69 CNY 1.37% Market Closed
Market Cap: ¥11.1B

Multiples-Based Value

The Multiples-Based Value for Tianjin Chase Sun Pharmaceutical Co Ltd (300026) under the Base Case is 3.29 CNY. Compared with the current market price of 3.69 CNY, the stock appears Overvalued by 11%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
3.29 CNY
Overvaluation 11%
Multiples-Based Value
Price ¥3.69
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Tianjin Chase Sun Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026
11.1B CNY 2 -167.6 735 735
US
Eli Lilly and Co
NYSE:LLY
883.9B USD 13.6 42.8 28.9 30.8
US
Johnson & Johnson
NYSE:JNJ
585.2B USD 6.2 21.8 15.2 18.6
UK
AstraZeneca PLC
LSE:AZN
237.5B GBP 5.4 31.2 17.2 24.2
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
US
Merck & Co Inc
NYSE:MRK
299.1B USD 4.6 16.4 10.1 12.3
CH
Novartis AG
SIX:NOVN
236.4B CHF 5.4 21.8 13.5 17.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 9
US
Pfizer Inc
NYSE:PFE
161B USD 2.6 20.7 7.9 10.5
US
Bristol-Myers Squibb Co
NYSE:BMY
120B USD 2.5 17 7.2 8.8
P/E Multiple
Earnings Growth PEG
CN
Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026
Average P/E: 22.4
Negative Multiple: -167.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
31.2
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
21.8
14%
1.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Tianjin Chase Sun Pharmaceutical Co Ltd
SZSE:300026
Average EV/EBITDA: 111.8
735
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
UK
AstraZeneca PLC
LSE:AZN
17.2
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.5
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.9
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett